此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Transcranial Sonography and Machine Learning for Schizophrenia Identification (TCS-ML-SZ)

2026年5月17日 更新者:Xiaocheng Zhang、Taizhou Second People's Hospital

Development and Validation of an Early Prediction Model for Schizophrenia Integrating Transcranial Sonography Structural Imaging and Machine Learning

Schizophrenia is a serious mental illness. Doctors usually diagnose schizophrenia by talking with patients, reviewing symptoms, and using clinical assessment. In early or less typical cases, diagnosis may be difficult.

This study will look at whether brain ultrasound information can help doctors identify features related to schizophrenia. The ultrasound scan used in this study is called transcranial sonography. It is a non-invasive scan that uses sound waves to look at brain structures through natural thin areas of the skull.

The study will include adults with schizophrenia and adults without a personal or family history of mental disorders. All participants will have a transcranial sonography scan and provide basic clinical information. The researchers will measure brain ultrasound features, including the substantia nigra, raphe nuclei, and third ventricle, and will combine these features with clinical information.

The main question is whether a computer model using ultrasound and clinical information can help distinguish adults with schizophrenia from adults without schizophrenia. The model is intended only as a research tool and possible future aid for doctors. It will not replace diagnosis by a psychiatrist and will not change the participant's usual medical care.

研究概览

地位

尚未招聘

详细说明

This is a prospective observational case-control study designed to develop and evaluate a machine-learning model for identifying schizophrenia using transcranial sonography (TCS) structural imaging features and clinical information.

Schizophrenia is clinically heterogeneous, and diagnosis depends mainly on clinical symptoms and psychiatric assessment. TCS is a non-invasive imaging method that can assess selected deep brain structures through the temporal acoustic window. Previous studies suggest that ultrasound features of structures such as the substantia nigra, raphe nuclei, and third ventricle may be related to neuropsychiatric disorders. This study will investigate whether TCS-derived structural imaging features, combined with clinical variables, can support auxiliary identification of schizophrenia.

Adults aged 18 to 65 years with schizophrenia diagnosed according to ICD-10 criteria and matched adults without a personal or family history of psychiatric disorders will be enrolled. The planned enrollment is 200 participants, including approximately 100 participants with schizophrenia and 100 healthy controls. Participants will undergo baseline TCS assessment and clinical data collection. No therapeutic intervention will be assigned by the investigators, and participation will not replace or alter usual clinical care.

TCS assessments will focus on selected brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width. Clinical information may include demographic characteristics, medical history, family history, disease course, medication history, and symptom assessment data when available. TCS measurements will be performed according to a standardized procedure, and image quality control will be conducted to reduce measurement variability.

The collected TCS and clinical variables will be integrated into a structured dataset for model development. Candidate machine-learning methods may include logistic regression, random forest, support vector machine, and XGBoost. Feature selection and model optimization will be performed within the model development process. Internal validation will be used to assess model performance, and additional independent data may be used for external validation if available.

Model performance will be evaluated using discrimination, calibration, and clinical utility metrics, including the area under the receiver operating characteristic curve, sensitivity, specificity, accuracy, F1 score, calibration assessment, and decision curve analysis where appropriate. Model interpretability will be explored using SHAP to assess the relative contribution of TCS imaging features and clinical variables.

The resulting model is intended as an auxiliary research tool for schizophrenia identification. It is not intended to make a definitive diagnosis, replace psychiatric assessment, or guide treatment decisions independently.

研究类型

观察性的

注册 (估计的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Zhejiang
      • Taizhou、Zhejiang、中国、317200
        • Taizhou Second People's Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Adults aged 18 to 65 years will be recruited from Taizhou Second People's Hospital and related recruitment channels. The study population will include participants with schizophrenia diagnosed according to ICD-10 criteria and healthy control participants without a personal or family history of psychiatric disorders. Healthy controls will be matched as far as possible to the schizophrenia group by basic demographic characteristics. All participants will undergo baseline transcranial sonography assessment and clinical data collection.

描述

Inclusion Criteria:

Schizophrenia group:

  1. Adults aged 18 to 65 years.
  2. Diagnosis of schizophrenia according to ICD-10 criteria by a psychiatrist.
  3. Able to complete clinical assessment and transcranial sonography examination.
  4. No other severe physical disease, neurological disease, or major psychiatric disorder.
  5. Written informed consent provided by the participant or legally authorized representative.

Healthy control group:

  1. Adults aged 18 to 65 years.
  2. No personal history of psychiatric disorders.
  3. No family history of psychiatric disorders.
  4. No severe physical disease, neurological disease, or major psychiatric disorder.
  5. Basic demographic characteristics matched as far as possible to the schizophrenia group.
  6. Able to complete clinical assessment and transcranial sonography examination.
  7. Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

  1. Severe physical disease or neurological disease.
  2. History of drug or alcohol abuse.
  3. Inability to complete clinical assessment or transcranial sonography examination.
  4. Inadequate temporal acoustic window or poor image quality preventing valid transcranial sonography measurements.
  5. Acute or clinically unstable state that prevents completion of study procedures.
  6. Comorbid major psychiatric disorder, such as major depressive disorder.
  7. Refusal or withdrawal of informed consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Schizophrenia Group
Adults aged 18 to 65 years with schizophrenia diagnosed according to ICD-10 criteria. Participants will undergo baseline transcranial sonography assessment and clinical data collection.
Baseline transcranial sonography assessment of brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width.
Healthy Control Group
Adults aged 18 to 65 years without a personal or family history of psychiatric disorders and matched as far as possible to the schizophrenia group by basic demographic characteristics. Participants will undergo baseline transcranial sonography assessment and clinical data collection.
Baseline transcranial sonography assessment of brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Area Under the ROC Curve of the Final TCS-Clinical Model
大体时间:Baseline; analyzed after completion of baseline data collection
The area under the receiver operating characteristic curve will be used to assess the ability of the final machine-learning model, based on transcranial sonography and clinical variables, to distinguish participants with ICD-10 schizophrenia from healthy controls. The reference standard will be clinical diagnosis according to ICD-10 criteria.
Baseline; analyzed after completion of baseline data collection

次要结果测量

结果测量
措施说明
大体时间
Sensitivity and Specificity of the Final TCS-Clinical Model
大体时间:Baseline; analyzed after completion of baseline data collection
Sensitivity and specificity will be calculated for the final model for distinguishing participants with schizophrenia from healthy controls, using a pre-specified or internally optimized classification threshold.
Baseline; analyzed after completion of baseline data collection
Other Classification Performance Metrics of the Final Model
大体时间:Baseline; analyzed after completion of baseline data collection
Accuracy, precision, recall, and F1 score will be calculated to further evaluate the classification performance of the final model for distinguishing participants with schizophrenia from healthy controls.
Baseline; analyzed after completion of baseline data collection
Calibration Performance of the Final TCS-Clinical Model
大体时间:Baseline; analyzed after completion of baseline data collection
Calibration will be evaluated by comparing predicted probabilities with observed diagnostic status using calibration plots, calibration slope, calibration intercept, and/or Brier score, as appropriate.
Baseline; analyzed after completion of baseline data collection

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月15日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年5月17日

首先提交符合 QC 标准的

2026年5月17日

首次发布 (实际的)

2026年5月22日

研究记录更新

最后更新发布 (实际的)

2026年5月22日

上次提交的符合 QC 标准的更新

2026年5月17日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The individual participant data generated or analyzed during this study will not be publicly shared because of participant privacy, the sensitive nature of psychiatric clinical data, and restrictions in the ethics approval and informed consent. Aggregated results will be reported in the published article.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅